(34%) and VA respondents (VA-MS 34%, MH/SA 27%, VA-ADR 40%). HHA and SNF respondents reported a similar average maximum number of daily injections per patient (2.7 and 2.9, respectively). Whereas, almost half of the HHA respondents reported restrictions on the number of daily nurse-administered injections that can be delivered (14% also reported that their agencies restricted the types of insulin that nurses can administer), only 10% of the VA-ADR and none of the SNF respondents reported any restrictions on the number of injections (about 18% of VA-MS and VA-ADR respondents reported restrictions on the type of insulin). CONCLUSIONS: Insulin treatment patterns and restrictions on T2D patients vary across settings, sometime substantially. There is evidence that care, as measured by nurse administered insulin injections, may be more restricted in home healthcare than in institutional settings such as SNFs and VA facilities. OBJECTIVES: Health care resource utilization and costs may be indicators of disease severity and overall health status. In observational studies, these factors could influence patients' probability of receiving or benefiting from a particular treatment. We compared pre-index utilization and costs in diabetes patients initiating saxagliptin versus other non-insulin anti-diabetic regimens. METHODS: Individuals age Ն18 years and with evidence of T2DM (ICD-9-CM 250.x0 or 250.x2) were identified from a US health plan database. Patients with Ն1 pharmacy claim for saxagliptin (SAXA) between August 1, 2009 and December 31, 2010 were assigned to the SAXA cohort, and patients with Ն1 pharmacy claim (August 1, 2009-December 31, 2010) for other oral anti-diabetic medications or GLP-1 analogs were assigned to the Other cohort. Patients were required to be naive to SAXA or the Other regimen for 12 months prior to the index pharmacy claim. Utilization and costs were measured during a 12 month (pre-index) period before treatment initiation. RESULTS: Pre-index, the SAXA cohort (Nϭ4763) had higher rates of all-cause ambulatory visits (14.7 vs. 13.9; pϽ0.001) and diabetes-related ambulatory visits (5.1 vs. 3.5; pϽ0.001) versus the Other cohort (Nϭ75,943). SAXA patients had higher pre-index all-cause pharmacy costs ($2808 vs. $1660; pϽ0.001) and diabetes-related total costs than Other patients ($3683 vs. $2854; pϽ0.001), driven by higher diabetesrelated ambulatory and pharmacy costs (both pϽ0.001). SAXA patients, however, had lower counts of pre-index all-cause and diabetes-related inpatient visits, allcause ED visits, and lower all-cause inpatient and ED costs than the Other cohort. CONCLUSIONS: In a managed health care setting, pre-index resource utilization and costs of patients initiating SAXA were higher for ambulatory services and pharmacy, but ED visits and inpatient stays were lower, compared with patients initiating other anti-diabetic regimens. These findings suggest SAXA prescribing patterns could be influenced by differences in patients' pre-index clinical characteristics and risk profiles, such as difficulty achieving glycemic control in the preindex period. 
OBJECTIVES: Out-of-pocket (OOP) cost as a component of insurance benefit design has been found to be a barrier to medication adherence or use of preventive care. This study aimed to assess the association of OOP share of total healthcare expenditure (THE) with diabetes monitoring in the United States. METHODS: This crosssectional study analyzed the household component data from the 2009 Medical Expenditure Panel Survey (MEPS). According to the American Diabetes Association guidelines, proper monitoring was defined as at least two A1c tests along with one eye or foot examination annually. The OOP share was measured by the percentage of annual self-paid healthcare expenses out of THE. Insurance coverage was categorized into any private, public only and uninsured. Logistic regression models were employed to control for social-demographics, health status, and treatments among subpopulations with different insurance coverage. Estimates were weighted to the total population (WTP OBJECTIVES: Health care resource utilization and costs may be indicators of disease severity and overall health status. In observational studies, these factors could influence patients' probability of receiving or benefiting from a particular treatment. We compared pre-index utilization and costs in diabetes patients initiating saxagliptin versus other non-insulin anti-diabetic regimens. METHODS: Individuals age Ն18 years and with evidence of T2DM (ICD-9-CM 250.x0 or 250.x2) were identified from a US health plan database. Patients with Ն1 pharmacy claim for saxagliptin (SAXA) between August 1, 2009 and December 31, 2010 were assigned to the SAXA cohort, and patients with Ն1 pharmacy claim (August 1, 2009-December 31, 2010) for other oral anti-diabetic medications or GLP-1 analogs were assigned to the Other cohort. Patients were required to be naive to SAXA or the Other regimen for 12 months prior to the index pharmacy claim. Utilization and costs were measured during a 12 month (pre-index) period before treatment initiation. RESULTS: Pre-index, the SAXA cohort (Nϭ4763) had higher rates of all-cause ambulatory visits (14.7 vs. 13.9; pϽ0.001) and diabetes-related ambulatory visits (5.1 vs. 3.5; pϽ0.001) versus the Other cohort (Nϭ75,943). SAXA patients had higher pre-index all-cause pharmacy costs ($2808 vs. $1660; pϽ0.001) and diabetes-related total costs than Other patients ($3683 vs. $2854; pϽ0.001), driven by higher diabetesrelated ambulatory and pharmacy costs (both pϽ0.001). SAXA patients, however, had lower counts of pre-index all-cause and diabetes-related inpatient visits, allcause ED visits, and lower all-cause inpatient and ED costs than the Other cohort. CONCLUSIONS: In a managed health care setting, pre-index resource utilization and costs of patients initiating SAXA were higher for ambulatory services and pharmacy, but ED visits and inpatient stays were lower, compared with patients initiating other anti-diabetic regimens. These findings suggest SAXA prescribing patterns could be influenced by differences in patients' pre-index clinical characteristics and risk profiles, such as difficulty achieving glycemic control in the preindex period. 
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OBJECTIVES:
To estimate the hospitalizations and its costs that can be attributed to diabetes mellitus (DM) among hospitalizations occurred in Brazilian Public Healthcare System (SUS) between 2008-2010. METHODS: Number of hospitalization and associated costs for study period was obtained through a review of government administrative claims database (DATASUS). Hospitalizations with a first-listed diagnosis of diabetes were added to hospitalizations estimated to be due to diabetes by attributable risk methodology (ARM). ARM is based on the formula: RAP i ϭ [P x (RRi -1)] / [P x (RRi -1) ϩ1], where RAP i is the fraction of population attributable risk for medical condition ЉiЉ due to diabetes, P represents prevalence rate of diabetes, and RRi is the relative risk of medical condition ЉiЉ for people with diabetes compared to those without it (ADA, 2003) . Diabetes prevalence was obtained from VIGITEL-2006, a nationwide random telephonic sample (54,369 individuals). Selfreported and expanded estimates according to diagnosis rate were used. Relative risks of hospitalization for chronic complications and general medical conditions for diabetic subjects were obtained from literature. Results were given for entire population and per 10,000 inhabitants according to national census bureau. RESULTS: According to self-reported data, a total of 896,727 hospitalizations were estimated to be related to DM per year in SUS. This corresponds to 47 hospitalizations per 10,000 inhabitants annually in the whole population and can reach up to 318,2 per 10,000 when considering the group aged 75ϩ. Annual hospitalization costs were estimated to be Brz$1,167,386,000 or Brz$61,197,90 per 10,000 inhabitants (and Brz$398,058.61/10,000 for 75ϩ population). When considering the expansion of self-reported cases according to diagnosis rate, it was estimate 1,353,161 hospitalizations (70,8 per 10,000) and a total annual cost of Brz$1,778,992 (Brz$ 93,140.65/10,000). CONCLUSIONS: DM and its complications are associated with a relevant economic burden to SUS, especially when considering the elderly population. 
PDB102 USE OF HEALTH CARE ADMINISTRATIVE DATABASES TO ESTIMATE THE BURDEN OF DIABETES MELLITUS: A POPULATION-BASED STUDY
OBJECTIVES:
To assess the epidemiologic and economic burden of diabetes mellitus (DM) from a large population-based study. METHODS: Lombardy Region includes 9.9 million individuals. Its DM population was identified through a data warehouse (DENALI), which matches with a probabilistic linkage demographic, clinical and economic data of different Healthcare Administrative databases. All individuals who during the year 2000 had an hospital discharge with a IDC-9 CM code 250.XX, and/or two consecutive prescriptions of drugs for diabetes (ATC code A10XXXX) within one year, and/or an exemption from co-payment health care costs specific for DM, were selected and followed up to 9 years. We calculated prevalence, mortality and health care costs (hospitalizations, drugs and outpatient examinations/visits) from the National Health Service's perspective. RESULTS: A total of 312,223 eligible subjects were identified. The study population (51% male) had a mean age of 66 (from 0.03 -105.12) years at the index date. Prevalence was 0.4% among subjects aged Ͻ45 years, 3.0% (46-55 years), 7.2% (56-65 years), 11.1% (66-75 years), 12.2% (76-85 years) and 10.1% (Ͼ85 years). Overall 43.4 deaths/1,000 patients/year were estimated, significantly (pϽ0.001) higher in men than women. Overall, 3,315€/patient-year were spent on average: hospitalizations were the cost driver (54.2% of total cost). Drugs contributed to 31.5%, outpatient claims represented 14.3% of total costs. As regards hospital costs, 35.6% was attributable to admissions for cerebro/cardiovascular reasons, 4.3% to admission for DM reasons, and 60.1% to any other reason. Class C drugs contributed to 33.5% of total drug costs, 21.8% was attributable to class A (16.7% to class A10) and 4.3% to class B (2.4% to class B01) drugs. CONCLUSIONS: . Merging different administrative databases can provide with many data from large populations observed for long time periods. DENALI shows to be an efficient instrument to obtain accurate estimates of burden of diseases such as diabetes mellitus. 
PDB103 PREDICTORS OF HOSPITAL READMISSIONS IN PATIENTS WITH DIABETES
